Detail akcie Novavax Rg online

Business Summary: Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Novavax Inc revenues increased 78% to $905.9M. Net income increased from $14.8M to $625.2M. Revenues reflect Net product sales increase from $102.2M to $632.4M. Net income benefited from Biotechnology segment income increase from $16.2M to $616.6M. Basic Earnings per Share excluding Extraordinary Items increased from $0.04 to $3.88.